Compare Novartis AG (NVS) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Schwab US Large Cap Growth ETF — how do they compare? Novartis AG trades at $152.59 (market cap $295.37B), while Schwab US Large Cap Growth ETF trades at $35.65. The key difference: Novartis AG pays a 3.07% dividend while Schwab US Large Cap Growth ETF pays none, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | SCHG | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $35.83 |
52-Week Low | $119.31 | $28.10 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
SCHG trades at $35.62, down 0.59% today, with a bullish technical outlook supported by moving averages. The ETF's concentrated portfolio of large-cap growth stocks, particularly in technology, drives performance but introduces concentration risk. Recent news highlights strong historical returns and institutional activity, though some analysts question current valuations.
Outlook remains positive given exposure to AI and technology growth trends, but investors face risks from high concentration in top holdings and sensitivity to interest rate changes. The low 0.04% expense ratio and tax efficiency are key advantages for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
